Implementation of metabolic screening tool to improve metabolic monitoring and reduce metabolic syndrome in psychiatric patients taking second-generation antipsychotic medications

Purpose of Project: Around 50% of individuals with serious mental illnesses who take second-generation antipsychotic medications are undiagnosed with metabolic syndrome and its comorbidities of hyperlipidemia, diabetes, and hypertension. This pilot study explored the gaps in current practices and the effects of metabolic screening through an evidence-based screening tool. The purpose of this study is to (1) improve clinician knowledge about metabolic syndrome, (2) screen and monitor patients with an evidence-based metabolic screening tool, and (3) refer patients that are at risk to primary care for metabolic syndrome treatment. Methodology: This study used a retrospective chart audit and a pre-and post-survey design to assess the effect of clinician educational intervention at baseline and two months regarding metabolic syndrome, metabolic screening, and monitoring psychiatric patients on second-generation antipsychotic medications. An evidence-based screening tool based on the American Psychiatric Association and American Diabetic Association guidelines was utilized, and demographic data and metabolic parameters were collected. The IOWA model is the theoretical framework used to support this study, and the Wilcoxon signed-rank test was used for data analysis. Results: A statistically significant improvement in clinicians’ knowledge after two months of incorporating the evidence-based metabolic screening tool into their clinical practice. Implication: There was an improvement in metabolic monitoring and consequential reduction of metabolic syndrome in psychiatric patients. This study demonstrates that increased proper screening by clinicians can positively impact patients' quality of life and lower annual health care expenditures.D.N.P.Includes bibliographical reference